Journey Medical (NASDAQ:DERM) Announces Earnings Results

Journey Medical (NASDAQ:DERM) posted its quarterly earnings results on Wednesday. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.30, Zacks reports. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The firm had revenue of $14.30 million for the quarter, compared to the consensus estimate of $14.21 million.

Journey Medical Trading Up 0.9 %

Shares of NASDAQ:DERM traded up $0.06 during trading on Friday, reaching $5.98. 13,226 shares of the company traded hands, compared to its average volume of 86,190. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. Journey Medical has a 52-week low of $3.20 and a 52-week high of $6.89. The firm has a market capitalization of $124.84 million, a price-to-earnings ratio of -6.36 and a beta of 0.97. The business’s fifty day moving average is $5.05 and its 200-day moving average is $5.16.

Insider Buying and Selling

In other Journey Medical news, CEO Claude Maraoui sold 14,905 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.01, for a total value of $74,674.05. Following the sale, the chief executive officer now owns 2,052,418 shares of the company’s stock, valued at $10,282,614.18. This trade represents a 0.72 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 105,831 shares of company stock valued at $536,622 over the last three months. 13.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research report on Thursday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $9.67.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.